Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company's lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. Pacira Pharmaceuticals, Inc. has a partnership with Thermo Fisher Scientific Pharma Services for the commercial production of EXPAREL. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [03/20/2019 08:01 PDT] PCRX Expected to Trade Up Short Term
• [03/15/2019 11:08 PDT] Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX), Up By 100.00% ($37.59) From $37.590 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [03/13/2019 07:56 PDT] PCRX Expected to Trade Up After Bullish Patterns Develop
• [03/07/2019 08:13 PST] sector Stocks Expected To Be Down After Top Correlated Stocks Fire Sell Signals.
• [03/07/2019 08:12 PST] PCRX Expected to Trade Down Short Term
• [03/01/2019 08:02 PST] PCRX Expected to Trade Up After Bullish Patterns Develop
• [02/14/2019 13:02 PST] Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX), Up By 100.00% ($37.77) From $37.770 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [02/12/2019 07:35 PST] PCRX Expected to Trade Up After Bullish Patterns Develop
• [02/06/2019 10:17 PST] PCRX Expected to Trade Down Short Term
• [02/04/2019 07:43 PST] PCRX Expected to Trade Down Short Term
• [01/31/2019 10:29 PST] Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX), Up By 100.00% ($38.71) From $38.710 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [01/25/2019 05:08 PST] PCRX Are Seasonally Ripe To Go Up In the Next Five Weeks